Diabetic Retinopathy Possibly Results From Poor Blood Sugar Control Associated With MTHFR Gene Polymorphism in Type 2 Diabetic Patients
Response to Yoshioka et al.
- Makiko Maeda, MS1,
- Isamu Yamamoto, MD1,
- Masakatsu Fukuda, MD, PHD2,
- Mari Nishida, BS1,
- Junko Fujitsu, MS1,
- Shinpei Nonen, MS1,
- Tsuyoshi Igarashi, MD, PHD3,
- Takashi Motomura, MD, PHD3,
- Makiko Inaba, MD3,
- Yasushi Fujio, MD, PHD1 and
- Junichi Azuma, MD1
- 1Department of Clinical Evaluation of Medicines and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
- 2Department of Ophthalmology, NTT West Japan Osaka Hospital, Osaka, Japan
- 3Second Department of Internal Medicine, NTT West Japan Osaka Hospital, Osaka, Japan
We appreciate the comments of Dr. Yoshioka et al. (1). As described previously (2), we excluded the patients with >133 μmol/l serum creatinine level. In addition, the patients with >300 mg/dl urinary protein levels did not participate in our study. We considered that these exclusions must elucidate the effects of the methylenetetrahydrofolate reductase (MTHFR) gene polymorphism, not the effects of nephropathy, on the progression of diabetic retinopathy (DR) in type 2 diabetic patients. We agree with their comment that we analyzed the correlation …
